Skip to main content
Erschienen in: Pediatric Drugs 4/2010

01.08.2010 | Review Article

Hereditary Angioedema in Childhood

An Approach to Management

verfasst von: Didier G. Ebo, Marjoke M. Verweij, Professor Kathleen J. De Knop, Margo M. Hagendorens, Chris H. Bridts, Luc S. De Clerck, Wim J. Stevens

Erschienen in: Pediatric Drugs | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Hereditary angioedema (HAE) is an inherited disorder characterized by recurrent, circumscribed, nonpitting, non-pruritic, and rather painful subepithelial swelling of sudden onset, which fades during the course of 48–72 hours, but can persist for up to 1 week. Lesions can be solitary or multiple, and primarily involve the extremities, larynx, face, esophagus, and bowel wall. Patients with HAE experience angioedema because of a defective control of the plasma kinin-forming cascade that is activated through contact with negatively charged endothelial macromolecules leading to binding and auto-activation of coagulation factor XII, activation of prekallikrein to kallikrein by factor XIIa, and cleavage of high-molecular-weight kininogen by kallikrein to release the highly potent vasodilator bradykinin. Three forms of HAE have currently been described. Type I and type II HAE are rare autosomal dominant diseases due to mutations in the C1-inhibitor gene (SERP1NG1). C1-inhibitor mutations that cause type I HAE occur throughout the gene and result in truncated or misfolded proteins with a deficiency in the levels of antigenic and functional C1-inhibitor. Mutations that cause type II HAE generally involve exon 8 at or adjacent to the active site, resulting in an antigenically intact but dysfunctional mutant protein. In contrast, type III HAE (also called estrogen-dependent HAE) is characterized by normal C1-inhibitor activity. The diagnosis of HAE is suggested by a positive family history, the absence of accompanying pruritus or urticaria, the presence of recurrent gastrointestinal attacks of colic, and episodes of laryngeal edema. Estrogens may exacerbate attacks, and in some patients attacks are precipitated by trauma, inflammation, or psychological stress. For type I and type II HAE, diminished C4 concentrations are highly suggestive for the diagnosis. Further laboratory diagnosis depends on demonstrating a deficiency of C1-inhibitor antigen (type I) in most kindreds, but some kindreds have an antigenically intact but dysfunctional protein (type II) and require a functional assay to establish the diagnosis. There are no particular laboratory findings in type III HAE.
Prophylactic administration of either 17α-alkylated androgens or synthetic antifibrinolytic agents has proven useful in reducing the frequency or severity of attacks. Plasma-derived C1-inhibitor concentrate, recombinant C1-inhibitor, ecallantide (DX88; a plasma kallikrein inhibitor) and icatibant (a bradykinin B2 receptor antagonist) have demonstrated significant efficacy in the treatment of acute attacks, whereas the C1-inhibitor concentrate has also provided a significant benefit as long-term prophylaxis. However, these drugs are not licensed in all countries and are not always readily available.
Literatur
1.
Zurück zum Zitat Quincke H. Concerning the acute localized oedema of the skin. Monatsh Prakt Derm 1882; 1: 129–31 Quincke H. Concerning the acute localized oedema of the skin. Monatsh Prakt Derm 1882; 1: 129–31
2.
Zurück zum Zitat Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 1888; 95: 362–7CrossRef Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 1888; 95: 362–7CrossRef
3.
Zurück zum Zitat Crowder JR, Crowder TR. Five generations of angioneurotic oedema. Arch Intern Med 1917; 20: 840–52CrossRef Crowder JR, Crowder TR. Five generations of angioneurotic oedema. Arch Intern Med 1917; 20: 840–52CrossRef
4.
Zurück zum Zitat Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am J Hum Genet 1996; 59: 308–19PubMed Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am J Hum Genet 1996; 59: 308–19PubMed
5.
Zurück zum Zitat Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians 1997; 109: 164–73PubMed Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians 1997; 109: 164–73PubMed
6.
Zurück zum Zitat Kalmar L, Hegedus T, Farkas H, et al. HAE: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2005; 25: 1–5PubMedCrossRef Kalmar L, Hegedus T, Farkas H, et al. HAE: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2005; 25: 1–5PubMedCrossRef
7.
Zurück zum Zitat Laimer M, Klausegger A, Aberer W, et al. Haploinsufficiency due to deletion within the 3’-UTR of C1-INH-gene associated with hereditary angioedema. Genet Med 2006; 8: 249–54PubMedCrossRef Laimer M, Klausegger A, Aberer W, et al. Haploinsufficiency due to deletion within the 3’-UTR of C1-INH-gene associated with hereditary angioedema. Genet Med 2006; 8: 249–54PubMedCrossRef
8.
Zurück zum Zitat Pappalardo E, Caccia S, Suffritti C, et al. Mutation screening of C1 inhibitor gene in l08 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45: 3536–44PubMedCrossRef Pappalardo E, Caccia S, Suffritti C, et al. Mutation screening of C1 inhibitor gene in l08 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45: 3536–44PubMedCrossRef
9.
Zurück zum Zitat Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008; 121: 181–8PubMedCrossRef Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008; 121: 181–8PubMedCrossRef
10.
Zurück zum Zitat Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417–29PubMedCrossRef Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417–29PubMedCrossRef
11.
Zurück zum Zitat Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med 1963; 35: 37–44PubMedCrossRef Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med 1963; 35: 37–44PubMedCrossRef
12.
Zurück zum Zitat Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52: 1402–9PubMedCrossRef Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52: 1402–9PubMedCrossRef
13.
Zurück zum Zitat Davis III AE. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628PubMedCrossRef Davis III AE. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628PubMedCrossRef
14.
Zurück zum Zitat Nielsen EW, Johansen HT, Hogasen K, et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996; 44: 185–92PubMedCrossRef Nielsen EW, Johansen HT, Hogasen K, et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996; 44: 185–92PubMedCrossRef
15.
Zurück zum Zitat Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213–8PubMed Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213–8PubMed
16.
Zurück zum Zitat Davis III AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006; 26: 633–51PubMedCrossRef Davis III AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006; 26: 633–51PubMedCrossRef
17.
Zurück zum Zitat Agostoni A, Ygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the Third C1 Esterase Inhibitor Deficiency Workshop and Beyond. J Allergy Clin Immunol 2004; 114: S51–131PubMedCrossRef Agostoni A, Ygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the Third C1 Esterase Inhibitor Deficiency Workshop and Beyond. J Allergy Clin Immunol 2004; 114: S51–131PubMedCrossRef
18.
Zurück zum Zitat Cicardi M, Zingale LC. The deficiency of C1 inhibitor and its treatment. Immunobiology 2007; 212: 325–31PubMedCrossRef Cicardi M, Zingale LC. The deficiency of C1 inhibitor and its treatment. Immunobiology 2007; 212: 325–31PubMedCrossRef
19.
Zurück zum Zitat Davis III AE. Hereditary angioedema: a current state-of-the-art review. III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7–12PubMedCrossRef Davis III AE. Hereditary angioedema: a current state-of-the-art review. III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7–12PubMedCrossRef
20.
Zurück zum Zitat Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101: 279–86PubMedCrossRef Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101: 279–86PubMedCrossRef
21.
Zurück zum Zitat Schachter M, Uchida Y, Longridge DJ, et al. New synthetic antagonists of bradykinin. Br J Pharmacol 1987; 92: 851–5PubMedCrossRef Schachter M, Uchida Y, Longridge DJ, et al. New synthetic antagonists of bradykinin. Br J Pharmacol 1987; 92: 851–5PubMedCrossRef
22.
Zurück zum Zitat Whalley ET, Nwator IA, Stewart JM, et al. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 430–3PubMedCrossRef Whalley ET, Nwator IA, Stewart JM, et al. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 430–3PubMedCrossRef
23.
Zurück zum Zitat Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057–63PubMed Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057–63PubMed
24.
Zurück zum Zitat Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842–56PubMedCrossRef Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842–56PubMedCrossRef
25.
Zurück zum Zitat Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26: 725–37PubMedCrossRef Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26: 725–37PubMedCrossRef
26.
Zurück zum Zitat Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213–7PubMedCrossRef Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213–7PubMedCrossRef
27.
Zurück zum Zitat Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546–50PubMedCrossRef Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546–50PubMedCrossRef
28.
Zurück zum Zitat Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286–9PubMedCrossRef Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286–9PubMedCrossRef
29.
Zurück zum Zitat Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098–104PubMedCrossRef Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098–104PubMedCrossRef
30.
Zurück zum Zitat Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136: 5076–83PubMedCrossRef Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136: 5076–83PubMedCrossRef
31.
Zurück zum Zitat Colman RW. Surface-mediated defense reactions: the plasma contact activation system. J Clin Invest 1984; 73: 1249–53PubMedCrossRef Colman RW. Surface-mediated defense reactions: the plasma contact activation system. J Clin Invest 1984; 73: 1249–53PubMedCrossRef
32.
Zurück zum Zitat Cicardi M, Bergamaschini L, Zingale LC, et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106: 650–4PubMedCrossRef Cicardi M, Bergamaschini L, Zingale LC, et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106: 650–4PubMedCrossRef
33.
Zurück zum Zitat Gupta S, Yu F, Klaustermeyer WB. New-variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function. Allergy 2004; 59: 557–8PubMedCrossRef Gupta S, Yu F, Klaustermeyer WB. New-variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function. Allergy 2004; 59: 557–8PubMedCrossRef
34.
Zurück zum Zitat Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006; 154: 542–5PubMedCrossRef Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006; 154: 542–5PubMedCrossRef
35.
Zurück zum Zitat Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206–15 Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206–15
36.
Zurück zum Zitat Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653–68PubMedCrossRef Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653–68PubMedCrossRef
37.
Zurück zum Zitat Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619–27PubMedCrossRef Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619–27PubMedCrossRef
38.
Zurück zum Zitat Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37: 1017–27PubMed Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37: 1017–27PubMed
39.
Zurück zum Zitat Ohela K. Hereditary angioneurotic oedema in Finland: clinical, immunological and genealogical studies. Acta Med Scand 1977; 201: 415–27PubMedCrossRef Ohela K. Hereditary angioneurotic oedema in Finland: clinical, immunological and genealogical studies. Acta Med Scand 1977; 201: 415–27PubMedCrossRef
40.
Zurück zum Zitat Zeana C. Hereditary angioedema due to deficit of C1 esterase inhibitor. Med Interne 1989; 27: 143–7PubMed Zeana C. Hereditary angioedema due to deficit of C1 esterase inhibitor. Med Interne 1989; 27: 143–7PubMed
42.
Zurück zum Zitat Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol 2005; 16: 288–94PubMedCrossRef Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol 2005; 16: 288–94PubMedCrossRef
43.
Zurück zum Zitat Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267–74PubMedCrossRef Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267–74PubMedCrossRef
44.
Zurück zum Zitat Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713–22CrossRef Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713–22CrossRef
45.
Zurück zum Zitat Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941–7PubMedCrossRef Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941–7PubMedCrossRef
46.
Zurück zum Zitat Sanchez A, Ecochard A, Maestracci M, et al. Hereditary angioedema causing colocolic intussusception. Arch Pediatr 2008; 15: 271–4PubMedCrossRef Sanchez A, Ecochard A, Maestracci M, et al. Hereditary angioedema causing colocolic intussusception. Arch Pediatr 2008; 15: 271–4PubMedCrossRef
47.
Zurück zum Zitat Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580–93PubMed Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580–93PubMed
48.
Zurück zum Zitat Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284: 2–9PubMedCrossRef Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284: 2–9PubMedCrossRef
49.
Zurück zum Zitat Sim TC, Grant JA. Hereditary angioedema: its diagnostic and management perspectives. Am J Med 1990; 88: 656–64PubMedCrossRef Sim TC, Grant JA. Hereditary angioedema: its diagnostic and management perspectives. Am J Med 1990; 88: 656–64PubMedCrossRef
50.
Zurück zum Zitat Winnewisser J, Rossi M, Spath P, et al. Type I hereditary angio-oedema: variability of clinical presentation and course within two large kindreds. J Intern Med 1997; 241: 39–46PubMedCrossRef Winnewisser J, Rossi M, Spath P, et al. Type I hereditary angio-oedema: variability of clinical presentation and course within two large kindreds. J Intern Med 1997; 241: 39–46PubMedCrossRef
51.
Zurück zum Zitat Sofia S, Casali A, Bolondi L. Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound 1999; 27: 537–40PubMedCrossRef Sofia S, Casali A, Bolondi L. Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound 1999; 27: 537–40PubMedCrossRef
52.
Zurück zum Zitat Shah TJ, Knowles WO, McGeady SJ. Hereditary angioedema with recurrent abdominal pain and ascites. J Allergy Clin Immunol 1995; 96: 259–61PubMedCrossRef Shah TJ, Knowles WO, McGeady SJ. Hereditary angioedema with recurrent abdominal pain and ascites. J Allergy Clin Immunol 1995; 96: 259–61PubMedCrossRef
53.
Zurück zum Zitat De Backer AI, De Schepper AM, Vandevenne JE, et al. CT of angioedema of the small bowel. Am J Roentgenol 2001; 176: 649–52 De Backer AI, De Schepper AM, Vandevenne JE, et al. CT of angioedema of the small bowel. Am J Roentgenol 2001; 176: 649–52
54.
Zurück zum Zitat Sunder TR, Balsam MJ, Vengrow MI. Neurological manifestations of angioedema: report of two cases and review of the literature. JAMA 1982; 247: 2005–7PubMedCrossRef Sunder TR, Balsam MJ, Vengrow MI. Neurological manifestations of angioedema: report of two cases and review of the literature. JAMA 1982; 247: 2005–7PubMedCrossRef
55.
Zurück zum Zitat Neri S, Ierna D, Sfogliano L. Unusual manifestations of hereditary angioedema. Eur J Emerg Med 2000; 7: 111–2PubMedCrossRef Neri S, Ierna D, Sfogliano L. Unusual manifestations of hereditary angioedema. Eur J Emerg Med 2000; 7: 111–2PubMedCrossRef
56.
Zurück zum Zitat Van Dellen RC, Myers RP. Bladder involvement in hereditary angioedema. Mayo Clin Proc 1980; 55: 277–8PubMed Van Dellen RC, Myers RP. Bladder involvement in hereditary angioedema. Mayo Clin Proc 1980; 55: 277–8PubMed
57.
Zurück zum Zitat De Knop KJ, Hagendorens MM, Stevens WJ, et al. Angioedema beyond histamine: an educational case series. Acta Clin Belg 2009; 64: 520–8PubMed De Knop KJ, Hagendorens MM, Stevens WJ, et al. Angioedema beyond histamine: an educational case series. Acta Clin Belg 2009; 64: 520–8PubMed
58.
Zurück zum Zitat Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema: I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986; 77: 749–57PubMedCrossRef Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema: I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986; 77: 749–57PubMedCrossRef
59.
Zurück zum Zitat Carugati A, Pappalardo E, Zingale LC, et al. C1-inhibitor deficiency and angioedema. Mol Immunol 2001; 38: 161–73PubMedCrossRef Carugati A, Pappalardo E, Zingale LC, et al. C1-inhibitor deficiency and angioedema. Mol Immunol 2001; 38: 161–73PubMedCrossRef
60.
Zurück zum Zitat Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065–70PubMedCrossRef Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065–70PubMedCrossRef
61.
Zurück zum Zitat Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498–503PubMedCrossRef Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498–503PubMedCrossRef
62.
Zurück zum Zitat Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147–54PubMedCrossRef Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147–54PubMedCrossRef
63.
Zurück zum Zitat Bailey E, Shaker M. An update on childhood urticaria and angioedema. Curr Opin Pediatr 2008; 20: 425–30PubMedCrossRef Bailey E, Shaker M. An update on childhood urticaria and angioedema. Curr Opin Pediatr 2008; 20: 425–30PubMedCrossRef
64.
Zurück zum Zitat Novembre E, Cianferoni A, Mori F, et al. Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol 2008; 40: 5–13PubMed Novembre E, Cianferoni A, Mori F, et al. Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol 2008; 40: 5–13PubMed
65.
Zurück zum Zitat Krishnamurthy A, Naguwa SM, Gershwin ME. Pediatric angioedema. Clin Rev Allergy Immunol 2008; 34: 250–9PubMedCrossRef Krishnamurthy A, Naguwa SM, Gershwin ME. Pediatric angioedema. Clin Rev Allergy Immunol 2008; 34: 250–9PubMedCrossRef
66.
Zurück zum Zitat Quastel M, Harrison R, Cicardi M, et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71: 1041–6PubMedCrossRef Quastel M, Harrison R, Cicardi M, et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71: 1041–6PubMedCrossRef
67.
Zurück zum Zitat Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002; 55: 145–7PubMedCrossRef Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002; 55: 145–7PubMedCrossRef
68.
Zurück zum Zitat Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57: 213–4PubMedCrossRef Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57: 213–4PubMedCrossRef
69.
Zurück zum Zitat Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149: 513–6PubMedCrossRef Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149: 513–6PubMedCrossRef
70.
Zurück zum Zitat Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res 1979; 13: 1043–6PubMedCrossRef Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res 1979; 13: 1043–6PubMedCrossRef
71.
Zurück zum Zitat Lockitch G, Halstead AC, Quigley G, et al. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988; 34: 1618–21PubMed Lockitch G, Halstead AC, Quigley G, et al. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988; 34: 1618–21PubMed
72.
Zurück zum Zitat Roach B, Kim Y, Jerome E, et al. Influence of age and sex on serum complement components in children. Am J Dis Child 1981; 135: 918–20PubMed Roach B, Kim Y, Jerome E, et al. Influence of age and sex on serum complement components in children. Am J Dis Child 1981; 135: 918–20PubMed
73.
Zurück zum Zitat Nielsen EW, Johansen HT, Holt J, et al. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35: 184–7PubMedCrossRef Nielsen EW, Johansen HT, Holt J, et al. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35: 184–7PubMedCrossRef
74.
Zurück zum Zitat Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review: VII. Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100: S30–40PubMedCrossRef Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review: VII. Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100: S30–40PubMedCrossRef
75.
Zurück zum Zitat Jackson J, Sim RB, Whelan A, et al. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722–4PubMedCrossRef Jackson J, Sim RB, Whelan A, et al. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722–4PubMedCrossRef
76.
Zurück zum Zitat Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987; 316: 1360–6PubMedCrossRef Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987; 316: 1360–6PubMedCrossRef
77.
Zurück zum Zitat Cicardi M, Beretta A, Colombo M, et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol 1996; 106: 475–80PubMedCrossRef Cicardi M, Beretta A, Colombo M, et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol 1996; 106: 475–80PubMedCrossRef
78.
Zurück zum Zitat Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274–81 Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274–81
79.
Zurück zum Zitat Donaldson VH, Wagner CJ, Davis III AE. An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor. J Lab Clin Med 1996; 127: 229–32PubMedCrossRef Donaldson VH, Wagner CJ, Davis III AE. An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor. J Lab Clin Med 1996; 127: 229–32PubMedCrossRef
80.
Zurück zum Zitat Varga L, Szeplaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema: strong correlation with the severity of disease in C1-INH concentrate naive patients. Mol Immunol 2007; 44: 1454–60PubMedCrossRef Varga L, Szeplaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema: strong correlation with the severity of disease in C1-INH concentrate naive patients. Mol Immunol 2007; 44: 1454–60PubMedCrossRef
82.
Zurück zum Zitat Farkas H, Harmat G, Kaposi PN, et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol 2001; 13: 1225–30PubMedCrossRef Farkas H, Harmat G, Kaposi PN, et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol 2001; 13: 1225–30PubMedCrossRef
83.
Zurück zum Zitat Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302: 542–6PubMedCrossRef Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302: 542–6PubMedCrossRef
84.
Zurück zum Zitat Phillips M. C1-inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 1980; 303: 526–7PubMedCrossRef Phillips M. C1-inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 1980; 303: 526–7PubMedCrossRef
85.
Zurück zum Zitat Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: l630–4CrossRef Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: l630–4CrossRef
86.
Zurück zum Zitat Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540–9PubMedCrossRef Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540–9PubMedCrossRef
87.
Zurück zum Zitat Visentin DE, Yang WH, Karsh J. C1-esterase inhibitor transfusions in patients with hereditary angioedema. Ann Allergy Asthma Immunol 1998; 80: 457–61PubMedCrossRef Visentin DE, Yang WH, Karsh J. C1-esterase inhibitor transfusions in patients with hereditary angioedema. Ann Allergy Asthma Immunol 1998; 80: 457–61PubMedCrossRef
88.
Zurück zum Zitat Bork K, Barnstedt SE. Treatment of l93 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161: 714–8PubMedCrossRef Bork K, Barnstedt SE. Treatment of l93 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161: 714–8PubMedCrossRef
89.
Zurück zum Zitat de Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247–54PubMedCrossRef de Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247–54PubMedCrossRef
90.
Zurück zum Zitat Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45: 1774–84PubMedCrossRef Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45: 1774–84PubMedCrossRef
91.
Zurück zum Zitat Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904–8PubMedCrossRef Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904–8PubMedCrossRef
92.
Zurück zum Zitat Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11–7PubMed Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11–7PubMed
93.
Zurück zum Zitat Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003; 134: 1088–94PubMed Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003; 134: 1088–94PubMed
94.
Zurück zum Zitat Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema: successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1: 326–30PubMedCrossRef Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema: successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1: 326–30PubMedCrossRef
95.
Zurück zum Zitat Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema [letter]. Am J Emerg Med 2004; 22: 633PubMedCrossRef Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema [letter]. Am J Emerg Med 2004; 22: 633PubMedCrossRef
96.
Zurück zum Zitat Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98: 383–8PubMedCrossRef Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98: 383–8PubMedCrossRef
97.
Zurück zum Zitat Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007; 33: 137–9PubMedCrossRef Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007; 33: 137–9PubMedCrossRef
98.
Zurück zum Zitat Dingle JT, Gordon J. Research monographs in cell and tissue physiology: proteinase inhibitors. Cambridge: Elsevier, 1988 Dingle JT, Gordon J. Research monographs in cell and tissue physiology: proteinase inhibitors. Cambridge: Elsevier, 1988
99.
Zurück zum Zitat Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29: 255–8PubMedCrossRef Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29: 255–8PubMedCrossRef
100.
Zurück zum Zitat Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15: 1077–90PubMedCrossRef Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15: 1077–90PubMedCrossRef
101.
102.
Zurück zum Zitat van Doorn MB, Burggraaf J, van DT, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876–83PubMedCrossRef van Doorn MB, Burggraaf J, van DT, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876–83PubMedCrossRef
103.
Zurück zum Zitat Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51–64PubMedCrossRef Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51–64PubMedCrossRef
104.
Zurück zum Zitat Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9: 310–23PubMed Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9: 310–23PubMed
105.
Zurück zum Zitat Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20: 139–42PubMedCrossRef Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20: 139–42PubMedCrossRef
106.
Zurück zum Zitat Maeda S, Miyawaki T, Nomura S, et al. Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 540–3PubMedCrossRef Maeda S, Miyawaki T, Nomura S, et al. Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 540–3PubMedCrossRef
107.
Zurück zum Zitat Jaffe CJ, Atkinson JP, Gelfand JA, et al. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol 1975; 55: 386–93PubMedCrossRef Jaffe CJ, Atkinson JP, Gelfand JA, et al. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol 1975; 55: 386–93PubMedCrossRef
108.
Zurück zum Zitat Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960; 53: 739–45 Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960; 53: 739–45
109.
Zurück zum Zitat Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol 1979; 64: 275–80PubMedCrossRef Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol 1979; 64: 275–80PubMedCrossRef
110.
Zurück zum Zitat Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444–8PubMedCrossRef Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444–8PubMedCrossRef
111.
Zurück zum Zitat Agostoni A, Cicardi M, Bergamaschini L, et al. C1-inhibitor concentrate for treatment of hereditary angioedema [letter]. N Engl J Med 1980; 303: 527PubMedCrossRef Agostoni A, Cicardi M, Bergamaschini L, et al. C1-inhibitor concentrate for treatment of hereditary angioedema [letter]. N Engl J Med 1980; 303: 527PubMedCrossRef
112.
Zurück zum Zitat Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181–7PubMedCrossRef Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181–7PubMedCrossRef
113.
Zurück zum Zitat Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294–8PubMedCrossRef Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294–8PubMedCrossRef
114.
Zurück zum Zitat Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80: 855–60PubMedCrossRef Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80: 855–60PubMedCrossRef
115.
Zurück zum Zitat Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194–6PubMedCrossRef Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194–6PubMedCrossRef
116.
Zurück zum Zitat Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005; 115: 864–9PubMedCrossRef Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005; 115: 864–9PubMedCrossRef
117.
Zurück zum Zitat Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007; 120: 654–8PubMedCrossRef Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007; 120: 654–8PubMedCrossRef
118.
Zurück zum Zitat Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Lett 2003; 86: 271–6PubMedCrossRef Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Lett 2003; 86: 271–6PubMedCrossRef
119.
Zurück zum Zitat Bork K, Pitton M, Harten P, et al. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353: 1066–7PubMedCrossRef Bork K, Pitton M, Harten P, et al. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353: 1066–7PubMedCrossRef
120.
Zurück zum Zitat Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36: 707–9PubMedCrossRef Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36: 707–9PubMedCrossRef
121.
Zurück zum Zitat Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23: 1355–90PubMedCrossRef Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23: 1355–90PubMedCrossRef
122.
Zurück zum Zitat Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92: 377–8PubMedCrossRef Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92: 377–8PubMedCrossRef
123.
Zurück zum Zitat Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972; 286: 808–12PubMedCrossRef Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972; 286: 808–12PubMedCrossRef
124.
Zurück zum Zitat Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452–4PubMedCrossRef Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452–4PubMedCrossRef
Metadaten
Titel
Hereditary Angioedema in Childhood
An Approach to Management
verfasst von
Didier G. Ebo
Marjoke M. Verweij
Professor Kathleen J. De Knop
Margo M. Hagendorens
Chris H. Bridts
Luc S. De Clerck
Wim J. Stevens
Publikationsdatum
01.08.2010
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 4/2010
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11532590-000000000-00000

Weitere Artikel der Ausgabe 4/2010

Pediatric Drugs 4/2010 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.